¿ Dow AgroSciences LLC, of Indianapolis, and Illinois Foundation Seeds Inc. (IFSI), of Champaign, closed an agreement in which Dow AgroSciences acquired IFSI shares in exchange for cash and an ownership interest in Dow¿s Indianapolis-based Advanced AgriTraits LLC subsidiary. IFSI received a 16.4 percent ownership interest in Advanced AgriTraits, plus $15 million in cash. Dow received newly issued Class B common stock, representing about 25 percent of IFSI¿s outstanding equity. The companies will share their respective technologies in crop traits and seed germplasm.
¿ Glaxo Wellcome plc, of London, said the FDA granted approval for expanded prescribing information on the use of Epivir (lamivudine), also known as 3TC, in infants, children and adolescents. The approval also includes an important revision to the indication for use of Epivir in combination with other antiretroviral agents for the treatment of HIV infection in adults and children. Epivir was developed by BioChem Pharma, of Laval, Quebec, and licensed to Glaxo.
¿ Hollis-Eden Pharmaceuticals Inc., of San Diego, reported that a study of its lead anti-HIV drug, HE2000, showed the drug significantly extended survival and showed a decrease in viral load versus animals in a control group. The study was presented at the 12th International Conference for Antiviral Research in Jerusalem.
¿ NaviCyte Inc., of San Diego, entered into an agreement with the R.W. Johnson Pharmaceutical Research Institute (PRI), a Johnson & Johnson company in New Brunswick, N.J., to collaborate on the use and development of NaviCyte¿s Pk-Informatics tools to identify new drug development candidates. PRI will provide data and make initial and milestone payments over the course of further development of NaviCyte¿s In Vitro Determination for Evaluation of Absorption (IDEA) simulation software system and database. NaviCyte, a wholly owned subsidiary of Trega Biosciences Inc., of San Diego, will license its software and computational models for use at PRI with compound libraries from PRI and other Johnson & Johnson affiliates. Pk-Informatics tools are designed to enable the prediction of pharmacokinetic outcomes in humans.
¿ Small Molecule Therapeutics Inc. (SMT), of Monmouth Junction, N.J., and Hybrigenics SA, of Paris, signed a collaborative research and development agreement to develop therapeutics for infectious diseases. SMT and Hybrigenics will partner with pharmaceutical companies on any potential drugs arising from the collaboration. Financial terms were not disclosed.